Mike is a Senior Executive with over 20 years R&D Pharma and Biotech Industry experience, including at Roche and Pfizer. He led the Anti-Infectives Research Group at Pfizer’s Sandwich R&D site and played a key role in progressing novel compounds through clinical trials, including maraviroc (Selzentry) a first-in-class HIV entry inhibitor.

As founder and CEO of three start-up Biotechs, Mike has successfully raised >£40m in dilutive and non-dilutive funds and has held Exec and Non-Exec Board positions in a number of early-stage companies, including Centauri Therapeutics Ltd, where he is retained as part-time CSO.

Mike trained in Molecular Biology and Biochemistry at the University of Durham, obtained his PhD at Warwick University and studied immunology and microbiology as a post-doctoral research fellow at St George’s Hospital Medical School, London. He is the co-author of more than 50 manuscripts and patents.